Location
Suwanee, GA
Start Date
10-5-2021 12:00 AM
End Date
14-5-2021 12:00 AM
Description
Introduction: Lymphedema commonly develops as a result of cancer treatments, including surgical removal of lymph nodes (LN). Research suggests there are 500-800 (LN) throughout the body. Deciding how many LN to remove and predicting possible severity of damage can become problematic when the range of LN in one area can vary by 30 LN.
Objective: The purpose of this study was to investigate more precise ranges of pelvic LN within cadaver samples.
Methods: Quantification of LN for number occurred on cadavers simultaneous with DO, PT, and PA students’ dissections. Demographics of the cadavers were 27 female, 16 male, 39 Caucasian, 3 African American, 1 Asian, with an age range of 42-102 and a mean of 70. The study utilized anatomical landmarks to identify and label the LN. Cadavers (N=43) inspected for lumbar LN and cadavers (N=86 sides) inspected for sacral, common, deep and superficial inguinal, and internal and external iliac LN.
Results: Quantitative analysis of the pelvic region LN revealed a power analysis value of 0.733 with 43 cadaver sample size (unpaired LN regions) and a value of 0.954 with a 86 cadaver sample size (paired LN regions). Analysis of LN in unpaired lumbar region revealed the true mean of the LN lies between 20-28 [CI=95] while previous data shows LN quantity ranging from 20-50. The true mean of LN in paired regions lies between [CI=95] from 6-10 (numerical range 5-30) for the common iliac, 2-3 (numerical range 2-3) for the sacral, 5-7 (numerical range 4-18) for the internal iliac, 10-13 (numerical range 5-25) for the external iliac, 2-4(numerical range 1-3) for the deep inguinal, and 9-12 (numerical range 4-25) for the superficial inguinal.
Conclusions: This study found reduced numbers of LN per 5 of the 7 regions from previous estimates. The common iliac and deep inguinal ranges did not change. These results could improve a surgeon’s informed decision on the number of LN to remove with staging and treating cancer.
Embargo Period
6-28-2021
Quantitative Analysis of Cadaveric Pelvic Lymph Nodes
Suwanee, GA
Introduction: Lymphedema commonly develops as a result of cancer treatments, including surgical removal of lymph nodes (LN). Research suggests there are 500-800 (LN) throughout the body. Deciding how many LN to remove and predicting possible severity of damage can become problematic when the range of LN in one area can vary by 30 LN.
Objective: The purpose of this study was to investigate more precise ranges of pelvic LN within cadaver samples.
Methods: Quantification of LN for number occurred on cadavers simultaneous with DO, PT, and PA students’ dissections. Demographics of the cadavers were 27 female, 16 male, 39 Caucasian, 3 African American, 1 Asian, with an age range of 42-102 and a mean of 70. The study utilized anatomical landmarks to identify and label the LN. Cadavers (N=43) inspected for lumbar LN and cadavers (N=86 sides) inspected for sacral, common, deep and superficial inguinal, and internal and external iliac LN.
Results: Quantitative analysis of the pelvic region LN revealed a power analysis value of 0.733 with 43 cadaver sample size (unpaired LN regions) and a value of 0.954 with a 86 cadaver sample size (paired LN regions). Analysis of LN in unpaired lumbar region revealed the true mean of the LN lies between 20-28 [CI=95] while previous data shows LN quantity ranging from 20-50. The true mean of LN in paired regions lies between [CI=95] from 6-10 (numerical range 5-30) for the common iliac, 2-3 (numerical range 2-3) for the sacral, 5-7 (numerical range 4-18) for the internal iliac, 10-13 (numerical range 5-25) for the external iliac, 2-4(numerical range 1-3) for the deep inguinal, and 9-12 (numerical range 4-25) for the superficial inguinal.
Conclusions: This study found reduced numbers of LN per 5 of the 7 regions from previous estimates. The common iliac and deep inguinal ranges did not change. These results could improve a surgeon’s informed decision on the number of LN to remove with staging and treating cancer.